martin

About Martin Glen

This author has not yet filled in any details.
So far Martin Glen has created 8 entries.

17 September 2018

Exonate – University of Bristol Enterprise Fund II investment

By |September 17th, 2018|

We are delighted to announce that the University of Bristol Enterprise Fund II, managed by Parkwalk, has invested in Exonate.

Exonate are developing a novel approach to modulating new vessel growth.  By controlling the balance of two contrasting forms of a protein called Vascular Endothelial Growth Factor (VEGF), they have demonstrated that they could not only treat models […]

16 May 2018

Ceres Power – announces strategic partnership with China’s Weichai Power

By |May 16th, 2018|

Parkwalk portfolio company Ceres Power Holdings plc (AIM: CWR) has announced a strategic collaboration with China’s Weichai Power (“Weichai”) comprising both product development and launch as well as a potential initial £17.0m equity investment by Weichai in Ceres Power.

The long term strategic relationship provides Ceres Power with access to the Chinese market, the world’s fastest growing […]

3 April 2018

Parkwalk closes Boxarr investment

By |April 3rd, 2018|

We are pleased to announce that the Parkwalk Opportunities Fund and University of Bristol Enterprise Fund I have made an investment in Boxarr, who provide analytical and data visualisation support to solve highly complex supply chain, systems, process and project business problems.

The company has developed a unique, versatile tool and powerful methodology that is unparalleled […]

28 March 2018

Oxford Endovascular – Parkwalk and UOIF IV investment

By |March 28th, 2018|

We have recently closed an investment in Oxford Endovascular for the Parkwalk Opportunities EIS Fund and the University of Oxford Innovation Fund IV.

Oxford Endovascular have developed Oxiflow, a novel, next generation ‘flow-diverter’ that diverts blood flow away from intracranial aneurysms at risk of rupture. The device is a metallic mesh tube, laser cut from Nitinol […]

20 February 2018

OxSyBio – Parkwalk closes Investment

By |February 20th, 2018|

We are delighted to announce that Parkwalk has participated in the funding of OxSyBio, which is seeking to commercialise IP generated by Professor Hagan Bayley at the University of Oxford.

The company has the unique ability to 3D print materials that have function derived from biology, but which are not living. The company is also able to print […]

Cytora – Parkwalk closes follow-on Investment

By |February 6th, 2018|

The University of Cambridge Enterprise Fund V and the Parkwalk Opportunities Fund  have closed an investment into Cytora, an artificial intelligence risk analytics spin-out from the University of Cambridge.

Cytora  raised $5.9 million in new financing from investors including divisions of QBE’s venture capital arm and Starr Cos.

QBE Ventures, Starr Global Holding, Cambridge Innovation Capital, Cambridge […]

9 January 2018

Ilika plc – Half-year report

By |January 9th, 2018|

Ilika (AIM: IKA), a pioneer in solid-state battery technology and materials innovation, announces its unaudited half yearly report for the six months ended 31 October 2017.
Operational Highlights
·     Exchanged detailed Stereax® performance data with over 60 potential OEM partners
·     Shipped sample batteries to 10 potential OEM partners for detailed technical evaluation
·     Three of these have progressed to development […]

28 November 2017

Parkwalk closes Opsydia investment

By |November 28th, 2017|

We are delighted to announce that the Parkwalk Opportunities Fund has made an investment in Opsydia, a spin-out company from the Department of Engineering Science at the University of Oxford, specialising in designing bespoke optical systems and laser fabrication processes for complex and unique ideas.